Literature DB >> 15808862

Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.

Abhinav Kumar1, Valsan Mandiyan, Yoshihisa Suzuki, Chao Zhang, Julie Rice, James Tsai, Dean R Artis, Prabha Ibrahim, Ryan Bremer.   

Abstract

Pim1, a serine/threonine kinase, is involved in several biological functions including cell survival, proliferation, and differentiation. While pim1 has been shown to be involved in several hematopoietic cancers, it was also recently identified as a target of aberrant somatic hypermutation in diffuse large cell lymphoma (DLCL), the most common form of non-Hodgkin's lymphoma. The crystal structures of Pim1 in apo form and bound with AMPPNP have been solved and several unique features of Pim1 were identified, including the presence of an extra beta-hairpin in the N-terminal lobe and an unusual conformation of the hinge connecting the two lobes of the enzyme. While the apo Pim1 structure is nearly identical with that reported recently, the structure of AMPPNP bound to Pim1 is significantly different. Pim1 is unique among protein kinases due to the presence of a proline residue at position 123 that precludes the formation of the canonical second hydrogen bond between the hinge backbone and the adenine moiety of ATP. One crystal structure reported here shows that changing P123 to methionine, a common residue that offers the backbone hydrogen bond to ATP, does not restore the ATP binding pocket of Pim1 to that of a typical kinase. These unique structural features in Pim1 result in novel binding modes of AMP and a known kinase inhibitor scaffold, as shown by co-crystallography. In addition, the kinase activities of five Pim1 mutants identified in DLCL patients have been determined. In each case, the observed effects on kinase activity are consistent with the predicted consequences of the mutation on the Pim1 structure. Finally, 70 co-crystal structures of low molecular mass, low-affinity compounds with Pim1 have been solved in order to identify novel chemical classes as potential Pim1 inhibitors. Based on the structural information, opportunities for optimization of one specific example are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808862     DOI: 10.1016/j.jmb.2005.02.039

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  43 in total

1.  Regulation of Skp2 levels by the Pim-1 protein kinase.

Authors:  Bo Cen; Sandeep Mahajan; Marina Zemskova; Zanna Beharry; Ying-Wei Lin; Scott D Cramer; Michael B Lilly; Andrew S Kraft
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

Review 2.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

3.  Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.

Authors:  George T Lountos; Joseph E Tropea; Di Zhang; Andrew G Jobson; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

4.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

Authors:  Zuping Xia; Christian Knaak; Jian Ma; Zanna M Beharry; Campbell McInnes; Wenxue Wang; Andrew S Kraft; Charles D Smith
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

5.  Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.

Authors:  Chao Zhang; Prabha N Ibrahim; Jiazhong Zhang; Elizabeth A Burton; Gaston Habets; Ying Zhang; Ben Powell; Brian L West; Bernice Matusow; Garson Tsang; Rafe Shellooe; Heidi Carias; Hoa Nguyen; Adhirai Marimuthu; Kam Y J Zhang; Angela Oh; Ryan Bremer; Clarence R Hurt; Dean R Artis; Guoxian Wu; Marika Nespi; Wayne Spevak; Paul Lin; Keith Nolop; Peter Hirth; Greg H Tesch; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

6.  Blocking UV-induced eIF2alpha phosphorylation with small molecule inhibitors of GCN2.

Authors:  Francis Robert; Chris Williams; Yifei Yan; Elizabeth Donohue; Regina Cencic; Stephen K Burley; Jerry Pelletier
Journal:  Chem Biol Drug Des       Date:  2009-07       Impact factor: 2.817

Review 7.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

8.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis.

Authors:  J J Gu; Z Wang; R Reeves; N S Magnuson
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

10.  Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.

Authors:  Alex N Bullock; Santina Russo; Ann Amos; Nicholas Pagano; Howard Bregman; Judit E Debreczeni; Wen Hwa Lee; Frank von Delft; Eric Meggers; Stefan Knapp
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.